Phase I/II Trial of Super-Selective Intraarterial Infusion of Erbitux (Cetuximab) and Avastin (Bevacizumab) for Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age.

Keywords: Antineoplastic Monoclonal Antibodies; Antineoplastics; Astrocytomas; Avastin Therapy; Bevacizumab Therapy; Biotechnology; Cancer; Central Nervous System; Cetuximab Therapy; Clinical Research; Clinical Trials and Studies; Contraception; Contraceptives; Craniotomy; Drugs and Therapies; EGFR Inhibitors; Erbitux Therapy; Gliomas; Health and Medicine; Immunologic Agents; Monoclonal Antibodies; Neurosurgical Procedures; Oncology; Oncology - Astrocytomas; Pharmaceuticals; Reproductive Medicine; Reproductive Techniques; Surgery; Surgical Procedures; Tyrosine Kinase Inhibitors; VEGF - VEGFR Inhibitors; VEGFR Inhibitors EN Antineoplastic Monoclonal Antibodies Antineoplastics Astrocytomas Avastin Therapy Bevacizumab Therapy Biotechnology Cancer Central Nervous System Cetuximab Therapy Clinical Research Clinical Trials and Studies Contraception Contraceptives Craniotomy Drugs and Therapies EGFR Inhibitors Erbitux Therapy Gliomas Health and Medicine Immunologic Agents Monoclonal Antibodies Neurosurgical Procedures Oncology Oncology - Astrocytomas Pharmaceuticals Reproductive Medicine Reproductive Techniques Surgery Surgical Procedures Tyrosine Kinase Inhibitors VEGF - VEGFR Inhibitors VEGFR Inhibitors 605 605 1 08/07/23 20230808 NES 230808 2023 AUG 8 (NewsRx) -- By a News Reporter-Staff News Editor at Immunotherapy Weekly -- Staff editors report on the newly launched clinical trial, NCT05956821, which has the following summary description: "This study assesses the safety and efficacy of repeat monthly dosing of super-selective intra-arterial cerebral infusion (SIACI) of cetuximab and bevacizumab in patients < 22 years of age." Patients of reproductive age must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. [Extracted from the article]